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Abstract
Since 2006, reprogrammed cells have increasingly been used as a biomedical research technique in addition to neuro-psychiatric
methods. These rapidly evolving techniques allow for the generation of neuronal sub-populations, and have sparked interest not
only in monogenetic neuro-psychiatric diseases, but also in poly-genetic and poly-aetiological disorders such as schizophrenia
(SCZ) and bipolar disorder (BPD). This review provides a summary of 19 publications on reprogrammed adult somatic cells
derived from patients with SCZ, and five publications using this technique in patients with BPD. As both disorders are complex
and heterogeneous, there is a plurality of hypotheses to be tested in vitro. In SCZ, data on alterations of dopaminergic transmis-
sion in vitro are sparse, despite the great explanatory power of the so-called DA hypothesis of SCZ. Some findings correspond to
perturbations of cell energy metabolism, and observations in reprogrammed cells suggest neuro-developmental alterations. Some
studies also report on the efficacy of medicinal compounds to revert alterations observed in cellular models. However, due to the
paucity of replication studies, no comprehensive conclusions can be drawn from studies using reprogrammed cells at the present
time. In the future, findings from cell culture methods need to be integrated with clinical, epidemiological, pharmacological and
imaging data in order to generate a more comprehensive picture of SCZ and BPD.
Introduction
Reprogrammed cells offer a window into a previously inaccessible
sphere of neuro-psychiatric disorders ﬁlling a gap between in vivo
observations of clinical cases and genetic analysis. So far, research
on the pathogenesis of psychiatric disorders on a cellular level has
been notoriously difﬁcult due to the lack of proper tissue models for
testing hypotheses or medicinal compounds. Tissue sampling has
given some insight into differential functioning of cells between
healthy subjects and patients, but cannot avoid the doubt inherent to
drawing conclusions from one tissue to another. No specimen can
be routinely taken from the central nervous system. Animal models
have unequivocally been helpful in testing compounds and generat-
ing hypotheses on the pathogenesis of various psychiatric disorders.
However, as psychiatric disorders are complex and multifactorial, it
is unlikely that a single animal model will be able to fully reproduce
their pathophysiology (Jones et al., 2011). Moreover, with somatic
disease models, we cannot assess whether the laboratory animal
does actually display the psychiatric symptoms we are trying to
investigate. While affective disorders comprise many symptoms
directly linked to behaviour, all of the Schneiderian ﬁrst-rank symp-
toms traditionally used to deﬁne core schizophrenia (SCZ) belong to
the realm of subjective experience (Schneider, 1957; Tandon et al.,
2009). We cannot ask a mouse whether it experiences thought
broadcasting or hears voices. Sampling of post mortem tissue avoids
uncertainty of pathology as it is possible to select patients based on
their clinical history. Those analyses are nevertheless confounded by
lack of information on earlier episodes, often lifelong medical treat-
ment, post mortem decay, and by death itself, which, among other
things, destroys ion gradients and alters tissue functioning and com-
position.
Since the publication of a robust method for the generation of
induced pluripotent stem cells (iPSC) by forced expression of four
transcriptional factors (Klf4, Oct4, Sox2 and c-Myc) by Takahashi &
Yamanaka, in (2006) the road to in vitro assays for neuronal cells
was paved (Takahashi & Yamanaka, 2006; Takahashi et al., 2007).
Those pluripotent cells can be differentiated into all three germ lay-
ers, so that easily accessible cells such as ﬁbroblasts or
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hematopoietic cells can be used to yield neuronal progenitor cells
and neurons. Inspired by the successful reprogramming of cells with
transcriptional factors, Vierbuchen et al. published a method for
directly converting mature somatic cells to functional neurons by
employing the factors Ascl1, Brn2 and Myt1l in 2010. Those cells
showed signs of mature neurons including neuronal membrane
potentials and the formation of functional synapses displaying short-
term plasticity (Vierbuchen et al., 2010). A host of reprogramming
techniques, either for direct transformation to a target cell, or to a
pluripotent state, has been published since.
Today, the notion of altered dopamine (DA) neurotransmission in
SCZ is no longer a hypothesis but supported by a wealth of evi-
dence derived from neuroimaging and genetic studies. Results from
the two research ﬁelds, found with a diverse array of methods, con-
verge on disturbances in pre-synaptic DA transmission as a key ele-
ment in the pathogenesis of SCZ. Imaging studies show increased
DA uptake and storage in the basal ganglia, and an enhanced release
of DA into the extracellular space in patients with SCZ. Large-scale
genetic studies show an association of SCZ with gene loci coding
for DA receptors and proteins involved in synaptic transmission.
However, integrating these ﬁndings to understanding the impact of
genetic and environmental risk factors for SCZ at a cellular level
emerges as a one of the key challenges on our way to new drug tar-
gets. Research in cultured neurons has the potential to help closing
this gap. Instead of just antagonizing DA D2/3 receptors at the post-
synaptic membrane, alternative ways for restoring DA transmission
at the pre-synaptic level will hopefully lead to more efﬁcient and
better tolerated ways to treat psychotic symptoms in major psychi-
atric disorders.
In this review, we the summarize ﬁndings from cell culture mod-
els of SCZ and bipolar disorder (BPD) and attempt to put these
ﬁndings into the context of current hypotheses. We will ﬁrst summa-
rize ﬁndings from cell culture models suggesting altered synaptic
transmission, then we describe evidence focussing on altered cell
maturation and early neurodevelopment, and then we report on liter-
ature focussing on cellular energy metabolism. An overview on
details and limitations of current reprogramming methods is found
in the appended ‘Techniques of cell reprogramming’ section.
Schizophrenia
Schizophrenia is a psychiatric disorder that affects roughly 1% of
the population worldwide (Saha et al., 2005). The clinical presenta-
tion of the disorder is highly heterogeneous, commonly comprising
positive symptoms such as delusions or hallucinations, negative
symptoms such as poverty of speech or motivational disturbance,
cognitive symptoms such as impaired working memory or executive
malfunctioning, and affective symptoms such as depressed or hypo-
manic mood (van Os & Kapur, 2009). A single patient can display
a plurality of symptoms, so that two patients, each being diagnosed
with the same disorder, need not share many psychopathological
traits.
Twin studies have shown that SCZ has a high heritability of up
to 90% (Sullivan et al., 2003), making it a natural target for cell-
based assays. There is a limited number of loci of relatively high
impact such as Disrupted in schizophrenia 1 (DISC1), ﬁrst charac-
terized as a risk factor in a Scottish family (Millar et al., 2000), or
the deletion 22q11.2, which causes the DiGeorge syndrome (Lind-
say et al., 1995). A vast number of low impact risk loci have been
identiﬁed over time, each contributing only marginally to the mani-
festation of the disorder in an individual (Duan, 2015). Yet, a signif-
icant proportion of heritability found in twin studies remains
unaccounted for (Manolio et al., 2009; Eichler et al., 2010). A sig-
niﬁcant proportion of SCZ-associated risk loci were signiﬁcantly
enriched by enhancers not only in neuronal, but also in peripheral
tissue (Psychiatric Genetics Consortium, 2014). Contributions to the
development of SCZ by immunological effectors are supported by
the recent observation of the involvement of complement component
4 (C4) in synaptic pruning (Sekar et al., 2016). Signiﬁcant enrich-
ment was also found in skeletal muscle and pancreatic islands,
which implies some involvement of non-neuronal tissues and is in
line with ﬁndings of disturbed metabolism in SCZ (Psychiatric
Genetics Consortium, 2014).
In 2011, Chiang et al. were the ﬁrst to transform cells derived
from patients suffering from SCZ to pluripotent stem cells utilizing
an integration-free plasmid vector (Chiang et al., 2011). Since this
pioneering work, a host of studies has dealt with patient-derived
reprogrammed cells. Most frequently, skin ﬁbroblasts were harvested
by punch biopsy and consequently transformed into iPSCs and dif-
ferentiated into neuronal progenitor cells (NPCs) and a neuron-like
state. Robicsek et al. (2013) were, to the best of our knowledge, the
only ones to prefer hair follicle keratinocytes over ﬁbroblasts for
their more efﬁcient reprogramming, availability and ectodermal
identity. Apart from low numbers of independent donors, a tendency
to recruit patients displaying strong signs of pronounced genetic
background such as high-risk mutations, high-incidence families and
early childhood onset of the disorder can be noted. Meir Jacobs’
review from 2015 gives an overview about possibilities and limita-
tions of iPSC-based studies in the ﬁeld of SCZ (Jacobs, 2015). A
technical review is provided by Duan, (2015).
Bipolar disorder
Bipolar disorder (BPD) is characterized by recurrent episodes of
depression and mania. Mania in particular is often accompanied by
psychotic states. Similar to SCZ, there is a high genetic contribution
to the disorder. In twin studies, heritability between 59 and 87%
was noted (Smoller & Finn, 2003). Among the available treatment
modalities, Lithium (Li+) displays the greatest efﬁcacy and a robust
anti-suicidal effect (Cipriani et al., 2013). Li+ interacts with cyclic
adenosine mono-phosphate (cAMP) response element-binding
(CREB) protein activity, the membrane potential of neurons via the
Na+/K+ ATPase, monoamine neurotransmitters, second messenger
cascades, glycogen synthase kinase (GSK) activity and transcrip-
tional factors (Alda, 2015). In the publications concerning repro-
grammed cell models derived from BPD patients reviewed here,
response to Li+ responsiveness plays a prominent role.
For an overview on patient-derived reprogrammed cell studies in
the ﬁeld of SCZ and BPD, see Tables 1 and 2.
Findings suggesting altered synaptic transmission
Schizophrenia
Alterations of monoamine neurotransmitter systems, most notewor-
thy DA, play a key role in the pathophysiology of SCZ (Howes
et al., 2015) and might be a suitable target for cell-based assays.
The DA hypothesis of SCZ was coined over 40 years, ago when the
DA depleting properties of reserpine (Carlsson et al., 1957) and the
DA receptor blocking properties of antipsychotic drugs were linked
to improvement of positive symptoms in patients with SCZ (Van
Rossum, 1966). Over the years, evidence in favour of disturbed DA
transmission as a key feature of the disorder has accumulated. Neu-
roimaging studies with positron emission tomography (PET) and
© 2016 The Authors. European Journal of Neuroscience published by Federation of European Neuroscience Societies and John Wiley & Sons Ltd.
European Journal of Neuroscience, 45, 45–57
46 U. Sauerzopf et al.
Table 1. Summary of the literature on ﬁndings in reprogrammed neuron-like cells derived from patients with schizophrenia and schizoaffective disorder
Publication Culture model Cases Cells Summary of ﬁndings
Chiang
et al. (2011)
Fibroblasts ? iPSCs
Episomal vector
(EBV based)
Plasmids (pEP4 EO2S
ET2K, pEP4 EO2S
EN2L, pEP4 EO2S EM2K)
Two cases chronic
SCZ, DISC1
mutation, siblings
No Differentiation
past iPSC
Proof of concept, for iPSC generation from SCZ
patients. First SCZ-derived iPSC line
Brennand
et al. (2011)
Fibroblasts ? iPSCs
Tetracycline induceable
Lentiviral vector (OCT4, SOX2,
KLF4, c-MYC, LIN28) ?
NPCs ? iNeurons
Five cases (three SCZ,
one SZA and drug
abuse, one Schizoid
personality and
anorexia nervosa):
Four in high-incidence
families
One childhood onset
Coriell Cell Repository
GM02038 GM01792
GM01835 GM02497
GM02503
Six age- and
ancestry-matched
controls
GM02937 GM03440
GM03651 GM04506
AG09319 AG09429
30% GAD65/67+
10% TH+
60% VGLUT1+
Cell-connectivity ↓ in SCZ
Neurite outgrowth ↓ in SCZ
PSD-95 ↓ in SCZ
Altered cAMP/WNT signalling
Loxapine rescues alterations
42 Genes affected by CNV of those only
CSMD1, MYH1, MYH4 showed > 1.3 fold
expression difference
596 Genes differently expressed (> 1.3 fold)
25% of those connected to SCZ
Pedrosa
et al. (2011)
Fibroblasts ? iPSC
Retroviral vector driven by
long terminal repeat (OCT4,
SOX2, KLF4, c-MYC) ? NPCs
? iNeurons
Neuronal differentiation
medium, WNT3A to support
glutamatergic cell fate
Three cases:
One del(22q11.2) SCZ
One childhood onset
One familial case
Two latter cases
Coriell Cell Repository
GM02039 GM02497
Two healthy subjects
Most cells are
glutamatergic and
express VGLUT1,
GRIK3, AMPA2,
GRIA2
Weak expression
of GAD1 and TH
In del(22q11.2), decline of OCT4 and NANOG
expression was markedly delayed
SMARCA2, JARID2, MYT1L and NPAS3 all of
which have been related to SCZ are expressed >
2 fold differently
> 2 fold differences in the expression in
SCZ-relevant genes CHGB, SLC25A27, C4A,
CHL1 and CTNNA2. NRXN3 was expressed
at > 3 fold difference
1207 Genes expr. diff. The most signiﬁcant GO
cluster comprised ‘neurogenesis’, ‘neuronal
differentiation’, ‘axon guidance’, and ‘adhesion’
Paulsen Bda
et al. (2012)
Fibroblasts ? iPSCs
pMX-based retroviral vector
(OCT4, SOX2, KLF4, c-MYC)
? NPCs
Retinoic acid and FGF2
One case,
clozapine-resistant SCZ
One age-matched
healthy control
Differentiation to
NPCs
AADC, DAT,
TH, ChAT and
LMX1B were
detected
Extramitochondrial O2 consumption ↑ in
SCZ-derived NPCs but not in iPSC or ﬁbroblasts
Level of reactive oxygen species ↑ in
SCZ-derived NPCs
Valproic acid reverts reactive oxygen species
level
No changes in ATP-coupled respiration
Robicsek
et al. (2013)
Hair follicle keratinocytes ?
iPSC
STEMCCA Lentivirus
reprogramming kit ? NPCs ?
iNeurons
Dual SMAD inhibition for
DA neurons
No use of WNT3A or retinoic
acid for GLUT differentiation
Three cases paranoid
SCZ, clozapine treated
Two healthy subjects
Differentiation to
DA and GLUT
neurons
SCZ-derived iDA NPCs show higher PAX6 and
reduced Nestin staining. Larger cell area.
Conversion to iDAs is incomplete in SCZ cells.
None express DAT, little release of dopamine
and very few b3-Tubulin+/TH+ cells. Outgrowth ↓
In Glut differentiation SCZ-derived cells express
no Tbr1; synapsin1 and PSD-95 ↓ indicative of
fewer synaptic contacts.
Mitochondiral dysfunction described in
SCZ-derived cells including keratinocytes
Hook
et al. (2014)
Fibroblasts ? iPSCs
Tetracycline inducible lentiviral
vector (OCT4, SOX2, KLF4,
c-MYC, LIN28) ? NPCs ?
iNeurons
BDNF, GDNF, dibutryl-cAMP
and ascorbic acid
Three cases, SCZ One
childhood onset
Coriell Cell Repository
GM01792 GM02038
GM2497
Three controls
American Type Culture
Collection
AG09429
Coriell Cell Repository
GM04506
One neonatal foreskin
Mixed population > 2 fold number TH+ neurons derived from
SCZ than healthy subjects’ iPSCs
Large differenced between patients
No increased transcription of TH
Elevated release of dopamine, norepinephrine
and epinephrine in SCZ-derived iPSC neurons
(continued)
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Table 1 (continued)
Publication Culture model Cases Cells Summary of ﬁndings
Yu et al.
(2014)
Fibroblasts ? iPSC
Tetracycline induceable
Lentiviral vector (OCT4, SOX2,
KLF4, c-MYC, LIN28) ? NPCs
DKK1 Cyclopamine, Noggin
? iNeurons
WNT3A, BDNF
Four SCZ cases,
derived from
Brennand et al. (2011)
Coriell Cell Repository
GM02038 GM01792
GM01835 GM02497
> 85% vGLUT+
< 15% GABA+
Hippocampal
DG granule
neurons
Lower fraction of active neurons in SCZ
Delayed conversion of NPCs to DG granule
neurons in SCZ
Reduced spontaneous neurotransmitter release
and spontaneous excitatory post-synaptic currents
in SCZ
Yoon
et al. (2014)
Fibroblasts ? iPSC
Sendai virus or episomal vector
in concordance with Chiang
et al. (2011) ? NPCs ?
iNeurons
Five cases
Three del(15q11.2)
no clinical information
Two DISC1 chronic
SCZ (identical
Chiang et al. (2011))
Three healthy subjects
Differentiation to
NPCs
No information
on dcell identity
CYFIP1 (a gene involved in 15q11.2 CNVs) and
Wave signalling mediators ACTR2/Arp2 SNPs
do while not causing risk for SCZ individually,
interact epistatically confer signiﬁcant risk for
SCZ.
This may be due to derogation of apical polarity
and adherens junctions in affected neurons
Wen
et al. (2014)
Fibroblasts ? iPSCs
Episomal vector (EBV based)
Plasmids(pEP4 EO2S ET2K,
pEP4 EO2S EN2L, pEP4
EO2S EM2K) ? NPCs
? iNeurons
Two cases from one
family
One SCZ
One major depression
Pedigree H, frameshift
mutation in DISC1
Three healthy subjects
(One neonatal foreskin,
two not affected
relatives)
Forebrain identity
90% of neurons
expressed VGLUT1
or a-GAMKII
few GAD6+7,
VGAT+ or TH+
Impaired synaptic transmission in DISC1 mutation
carriers. Defect in depolarization induced vesicle
release.
1–2 weeks post-conversion DISC1 carriers
display larger soma and dentritic length.
A large number of genes is differentially
expressed at 4 weeks. Those are linked to
synaptic transmission, dentritic spines and CNS
development. 89 genes linked to mental
Disorders
Hashimoto-Torii
et al. (2014)
Fibroblasts ? iPSCs
Tetracycline induceable
Lentiviral vector (OCT4, SOX2,
KLF4, c-MYC, LIN28)
? NPCs ? iNeurons
Four cases,
No further
characterization
Five controls
No differentiation
past NPCs
No information
on cell identity
Following environmental challenges with methyl
mercury and ethanol, NPCs derived from patients
display sig. larger variability in HSP70
expression than healthy subjects. Means of
HSP70 expr. are unchanged. GAPDH expression
shows no difference
Paulsen
Bda et al.
(2014)
Fibroblasts ? iPSCs
pMX-based retroviral vector
(OCT4, SOX2, KLF4, c-MYC)
? NPCs
Retinoic acid and FGF2
One clozapine-resistant
patient SCZ
Two healthy subjects
No differentiation
past NPCs
Signiﬁcantly more Zn+ and K+ in SCZ-derived
NPC (but not iPSC) clones. Valproate reduced
Zn+ and K+ levels to normal without affecting
other trace elements as measured by syncrotron
radiation x-ray microﬂurescence spectrometry
Topol
et al. (2015)
Fibroblasts ? iPSC
Tetracycline induceable
lentiviruse vectors (OCT4,
SOX2, KLF4, c-MYC, LIN28)
? NPCs ? iNeurons
Four cases with SCZ
Coriell Cell Repository
GM02038 GM01792
GM01835 GM02497
Six healthy subjects
Study in NPCs
forebrain identity
Signiﬁcant over-expression of translation-related
proteins with globally increased protein levels.
Overexpression of protein clusters related to
ribosome/RNA binding, nucleosome, chromatin,
nucleocytoplasmatic and transport.
Increased Translation is observed in NPCs but
not in iPSCs. Primary Fibroblasts show a trend
towards increased synthesis. The ﬁndings cannot
be explained by cell size. No link between
aberrant migration and protein over expression
could be established
Brennand
et al. (2015)
Fibroblasts ? iPSCs
Tetracycline induceable
Lentiviral vector (OCT4, SOX2,
KLF4, c-MYC, LIN28)
? NPCs ? iNeurons
Four cases with three
SCZ 1 SZA
Two patients are
siblings
Coriell Cell Repository
GM02038 GM01792
GM01835 GM02497
Six healthy subjects
Coriell Cell Repository
GM03440 GM03651
GM04506
American Type
Culture Collection
AG09319 AG09329
One neonatal foreskin
CRL-2522
Forebrain NPCs
and early
neurons
NPC and early neuron gene expression resembles
ﬁrst trimester forebrain neurons.
SCZ and healthy subjects display similar gene
expression and spatial and temporal identity.
NCAM1, NLG1, NRXN1 and NRXN3 ↓ in SCZ
481 genes expressed at > 1.3 fold difference
between SCZ and healthy subjects in NPCs;
differences are conserved in older stages.
Aberrant cell migration in SCZ cells (no effect
of loxapine or clozapine)
Morphological difference in mitochondria
Increased oxidative stress in SCZ
Passeri
et al. (2015)
Fibroblast direct conversion to
iNeurons
Lentiviral vector (ASCL1,
POU3F2, MYT1L) novel
conversion media
Four cases, childhood
onset
2 del(22q11.2)
1 del(16p11.2)
1del(16p11.2)dupl.
(22q13.3)
Five healthy subjects
Mostly
glutamatergic
del(16p11.2) is associated with signiﬁcantly higher
rate of conversion to neuron-like cells
(continued)
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single-photon emission computed tomography (SPECT) have identi-
ﬁed the pre-synapse as the most probable origin of DA dysregula-
tion (Howes et al., 2012). The cultivation of dopaminergic midbrain
neurons thus holds great promise for modelling key pathophysiolog-
ical traits of SCZ.
There are some ﬁndings regarding alterations of the dopaminergic
system derived from non-reprogrammed cells. Utilizing PC12 cells,
a cell line derived from rodent adrenal tissue, Kantor et al. (2002)
succeeded in inducing amphetamine sensitization, a phenomenon
endogenously occurring in patients with SCZ (Howes et al., 2012).
The same group showed protein kinase C (PKC) and mitogen-acti-
vated protein kinase (MAP kinase) to be necessary for amphetamine
sensitization to occur (Park et al., 2002, 2003) The observation of a
biological event thought to be of relevance for DA dysfunction in
SCZ in a non-human, non-neuronal cell line supports the hope for
cell-based assays to further elucidate alterations of the DA system in
SCZ. Nevertheless, impairments of DA transmission could not yet
be reliably modelled in reprogrammed neurons derived from patients
with SCZ. Hook et al. (2014) described a more than 2-fold eleva-
tion in the number of tyrosine hydroxylase (TH) positive (TH+)
neurons in cells derived from patients with SCZ compared to those
derived from healthy subjects. Moreover, they observed elevated
K+-induced release of DA, epinephrine and norepinephrine in
patient-derived cells. Robicsek et al. (2013) observed severely ham-
pered differentiation to dopaminergic and glutamatergic neurons in
SCZ-derived cells. None of the cells expressed the dopamine trans-
porter (DAT). Tyrosine hydroxylase and b3-tubulin were expressed
only at minuscule levels. Dopaminergic neuronal cells displayed
Table 1 (continued)
Publication Culture model Cases Cells Summary of ﬁndings
D’Aiuto
et al. (2015)
Fibroblasts ? iPSC ? NPCs ?
iNeurons
One case SCZ Line
5404
One control neonatal
foreskin
HFF1-S
Differentiation
to glutamatergic
neurons
Herpes simplex virus I can establish quiescent
infection in iPSC-derived neurons and alters gene
expression in cognition relevant pathways. No
information provided on differences regarding
diagnosis
Zhao
et al. (2015)
Fibroblasts ? iPSC
Nucleofection plasmids (OCT4,
SOX2, KLF4, L-MYC, LIN28
and p53 shRNA) ? NPCs ?
iNeurons
Six cases
4 del(22q11.2)
(1 SCZ, 3 SZA)
Two childhood
onset SCZ
Six healthy subjects
GABAergic
glutamatergic
mixed population
45 miRNAs expressed differently according to
diagnosis.
Of 6 miRNAs with genome wide sign. down
regulated in del(22q11.2) cells; 4 map to affected
region (miRNA-1306-3p, miR-1286,
miRNA-1306-5p and miRNA-185-5p) and 2
do not (miRNA-3175, miRNA-3158-3p)
miRNA-34 family miRNAs showed marked
increase but did not reach genome wide sign.
miRNA-4449, miRNA-146b-3p, and
miRNA-23a-5p showed the greatest increase in
expression.
No upregulated miRNAs reached genome wide
sign
Lee
et al. (2015)
Cohort 2:
Fibroblasts ? iPSCs Sendai
viral vector ? NPCs
? Neurons
Dual SMAD inhibition
Lentiviral vector (Ngn2
induction) to yield
glutamatergic neurons
One case (offspring)
SZA heterozygous
CNTNAP2 deletion
Seven healthy
subjects (father)
heterozygous
CNTNAP2 deletion
(mother) no mutation
Five unrelated
healthy subjects
Forebrain identity
and glutamatergic
neurons
late oligodendrocyte
precursor cells
(15% O4+/MBP+
mature
oligodendrocytes)
as well as ~15%
astrocytes and ~20%
neurons
Increased expression of the full length transcript
in a phenotype-speciﬁc way. In the SZA patient
in 6-weeks old neurons. Not affected father
displayed increased transcription only in NPCs.
NPC migration was signiﬁcantly reduced in the
SZA case, but not in the healthy carrier (father).
In SZA (offspring) oligodendrocyte precursor
cells predominantly the mutated allele of
CNTNAP2 was expressed, whereas the father
primarily expressed the wild-type allele
Murai
et al. (2016)
Fibroblasts ? iPSCs
Lentiviral vector
? NPCs
Two cases SCZ
Both from pedigree
H with DISC1
frameshift mutation
Three healthy
subjects
No differentiation
past NSC
miR-219 expression is elevated in DISC1 carrier
NSCs.
miR-219 acts downstream of TLX and leads to
reduced NSC proliferation
Topol
et al. (2016)
Cohort 1:
iPSCs ? NPCs ? Neurons
Tetracycline induceable
Lentiviral vector (OCT4, SOX2,
KLF4, c-MYC, LIN28)
Cohort 2:
Fibroblasts ? iPSCs Sendai
viral vector ? NPCs
? Neurons
Dual SMAD inhibition
Cohort 1:
Four SCZ cases,
six controls
Cohort 2:
10 childhood onset
SCZ cases
10 not related
healthy subjects
NPCs and early
neurons,
forebrain identity
SCZ NPCs display reduced miR-9 levels. A subset
(~50%) of SCZ are below 25% quantile of
healthy subjects’ NPCs. Perturbed miRNA-9
levels can be observed in NPCs and early
neurons but not after prolonged (6 weeks)
maturation
miRNA-9 is correlated with impaired radial
migration of NPCs in SCZ. Overexpression of
miRNA-9 rescues migration phenotype.
Non-genomic as well as genomic causes might
affect altered miRNA-9
Altered miRNA-9 expression affects multiple
genes on transcript and protein level
iPSC, induced pluripotent stem cells; SCZ, schizophrenia; NPC, neuronal progenitor cell; SZA, schizoaffective disorder; CNV, copy number variation; iNeuron:
induced neuron-like cell; iDA, induced dopaminergic neuron.
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altered cell area, neurite number and length. Glutamatergic neurons
failed to express T-box, brain, 1 (Tbr1) alongside with decreased
expression of synapsin1 and postsynaptic density protein 95
(PSD-95) indicating reduced synaptic contacts. A possible explana-
tion for those divergent results may be the different origin of adult
somatic cells used in those experiments: While Hook et al.
Table 2. Summary of the literature on ﬁndings in reprogrammed neuron-like cells derived from patients with bipolar disorder
Publication Culture model Cases Cells Summary of ﬁndings
Chen
et al. (2014)
Fibroblasts ? iPSC
Retroviral vector (OCT4,
SOX2, KLF4, c-MYC)
iPSC ? NPC ? iNeurons
Embryoid body medium
and neuron induction
medium
Three cases BPD type 1
2 Li+ responders, one
non-responder
three age-matched
healthy controls
Forebrain phenotype
VGlut+
pyramidal-shaped
neurons,
GABA+ interneurons,
scattered serotonergic
and dopaminergic
neurons
2547 genes expression diff. between BPD/healthy
subjects’ iPSC
186 genes expression ↑ BPD (> 1.5 fold) in iPSC
46 genes expression ↓ BPD (> 1.5 fold) in iPSC
1312 genes expression diff. between BPD/healthy
subjects’ iN
140 genes expression ↑ BPD (> 1.5 fold) in iN
46 genes expression ↓ BPD (> 1.5 fold) in iN
BPD-derived neurons show higher expression of
DICER1, NKX2-1 and PAX2 but lower expression
of EMX2 and HOXA1,6,7
Li+ pre-treatment reduces Ca++ transient and wave
amplitude in BPD-derived iNs compared to healthy
subject derived iNs
Wang
et al. (2014)
Fibroblasts direct conversion
Lentiviral vector
(miRNA-9/9*-123,
NEUROD2, ASCL1,
MYT1L)
Twelve cases BPD type 1
and history of
Li+ treatment
Six responders
Six non-responders
Six healthy subjects
Heterogeneous cell
population, no
capability to produce
action potentials
without further
differentiation and
expressing neuronal
as well as stem-cell
markers
Cells derived from Li+ responders show
greater adhesion than cells from
Li+ non-responders as measured by
ΔPWV (Peak Wave Length) in a BIND scanner
Madison
et al. (2015)
Fibroblasts ? iPSC
Retroviral vector (vector
(OCT4, SOX2, KLF4,
c-MYC))
iPSC ? NPC ? iNeurons
NPC medium, neurobasal
medium
Two offspring
(BPD Type 1)
GM05224 GM05225
Coriell Cell Repository
Two parents (healthy)
GM08330 GM08329
Mixed population Neurons could be generated from all healthy subjects’
iPSC but only 2/6 BPD iPSC lines. NPCs could be
generated from all lines, but not propagated beyond
4–5 passages. No expression of PAX6
Bromodeoxyuridine staining (proliferation) ↓ in BPD
NPCs
BPD neurons show ↓↓ viability after 2 weeks of
differentiation; hardly any neurons were found
after 6 weeks
In iPSCs and ﬁbroblasts, hardly any difference
between BPD and healthy subjects
In NPCs, 18 genes > 1.5 fold expression
Mertens
et al. (2015)
Fibroblasts ? iPSC ? NPCs
Cyto-Tune Sendai
reprogramming kit
(commercial) ? NPCs
DKK1 Cyclopamine,
Noggin ? iNeurons
WNT3A, BDNF
Six cases, BPD Type 1
Recruited during a
prospective trial for
Li+ monotherapy
(three Li+ responders,
three Li+
non-responders)
Four healthy subjects
Hippocampal dentate
gyrus (DG)
granule cell-like
neurons
> 80% VGLUT1+
2–7% GABAergic
(characterized by
GABA release)
Expression of mitochondrial genes in BPD ↑
Overall smaller mitochondria
mitochondrial function in JC-1 Assay in BPD ↑
Increased excitability in BPD iPSC neurons. Altered
action potential frequency, Ca++ signalling PKA/C
signalling.
In Li+ responders, action potential frequency was
attenuated by Li+ but not in non-responders. Li+ alters
gene expression differently in responders and
non-responders and seems to rescue disease relevant
genes. Li+ increases mitochondria size.
Electrophysiological alterations in non-responders
were attenuated by lamotrigine
Bavamian
et al. (2015)
iPSC ? NPCs
Retroviral vector (vector
(OCT4, SOX2, KLF4,
c-MYC))
NPCs?iNeurons
In NPC and neuronal
differentiation media
Fibroblasts ? iNeuron:
direct conversion from
ﬁbroblasts
Lentiviral vector
(miRNA-9/9*-123,
NEUROD2, ASCL1,
MYT1L)
iPSC: I case BPD type 1
Coriell Cell Repository
GM05224 and one
healthy subject
GM08330
iN ﬁve cases
BPD type 1
Not stated miRNA-34a ↑ in BPD patient cerebellum slices
(without Li+ treatment) as well as in both cell models
25 putative miR-34a targets were identiﬁed. ANK3,
CACNA1C, CACNB3, ODZ4, DDN, and KLC2
overlap with BPD GWAS loci.
miRNA-34a targets were downregulated with increased
expression of the miRNA in NPCs and early neurons
derived from a BPD patient.
ANK3 and CACNB3 were up regulated as miRNA-34a
was blocked in healthy subject and BPD-derived iPSC
neurons.
miRNA-34a impairs pre- and post-synaptic
development; dentritic branching ↓
iPSC, induced pluripotent stem cells; BPD, bipolar disorder; NPC, neuronal progenitor cell; iNeuron/iN, induced neuron-like cell.
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reprogrammed skin ﬁbroblasts, Robiscek et al. used hair-follicle ker-
atinocytes. Other variations in the reprogramming procedure, includ-
ing alternate induction of ventral-dorsal axis identity of the yielded
cell population are discussed in: Hartley et al., 2015. Yu et al.
(2014) describe reduced spontaneous neurotransmitter-release and
spontaneous post-synaptic currents in SCZ-derived cells mimicking
hippocampal dentate gyrus granule neurons consisting largely of
vesicular glutamate transporter 1-positive (vGLUT1+) cells and a
minority of gamma-aminobutyric acid-positive (GABA+) cells.
Deﬁcits in depolarization induced vesicle release and impaired
synaptic transmission were reported by Wen et al. (2014) The inves-
tigated cell cultures comprised more than 90% cells expressing
vGLUT1 or alpha Ca++/calmodulin-dependent protein kinase II (a-
CAMKII) neurons derived from two patients suffering from SCZ
and major depression from a pedigree carrying a frame shift muta-
tion in DISC1. a-CAMKII has been found to be of relevance for the
induction of sensitization to amphetamine (Steinkellner et al., 2014).
A causative relationship between DISC1 mutation and synaptic dys-
function was established by generating knock-in iPSC lines of an
unaffected family member and a non-related control (Wen et al.,
2014).
Brennand et al. (2011) examined a set of ﬁve SCZ cases, four of
which originated from high-incidence families. Alongside with the
reduced expression of the post-synaptic marker PSD-95, which was
later found to be attenuated also by Robicsek et al. (2013), reduced
neuronal connectivity was observed employing a rabies virus assay.
Alterations in the expression of genes relevant to glutamate, Wnt
signalling and cAMP signalling, were noted by the authors. Reduced
synaptic connectivity was rescued by treatment of induced neurons
with the antipsychotic loxapine. Loxapine also increased the expres-
sion of neuregulin 1 (NRG1) and various glutamate receptors
(GRIK1, GRM7 and GRIN2A), as well as the expression of ADCY8,
PRKCA, WNT7A and TCF4. No positive effects on connectivity
were observed with clozapine, olanzapine, risperidone and thiori-
dazine (Brennand et al., 2011).
Bipolar disorder
In a prospective design, Mertens et al. (2015) observed six patients
with BPD on Li+ monotherapy. Notably, reduced cellular activity as
described by Yu et al. was not detected here, but rather an increase
in excitability, although identical methods were employed. This indi-
cates a disease-speciﬁc alteration. Cellular hyper-excitability in
BPD-derived cells was attenuated by Li+ treatment in clinical Li+
responders, but not in Li+ non-responders. The latter displayed
attenuation of electrophysiological alterations by lamotrigine. The
authors noted much larger changes in gene-transcription in Li+
responders when compared to Li+ non-responders bringing gene
expression closer to what is found in healthy subjects. Among the
rescued genes, there were 84 directly involved in putative pathologi-
cal processes, among those PKA/C regulation, neuronal ﬁring rate
and Ca++ signalling (Mertens et al., 2015).
Li+ was shown to reduce Ca++ transient and wave amplitude
signiﬁcantly more in BPD-derived neurons than healthy subjects-
derived neurons at 12 weeks post-differentiation (Chen et al.,
2014).
Findings suggesting disturbed neurodevelopment
As iPSC models mimic neuronal development from a very early
stage, perturbations of normal developmental steps can be observed
on a single-cell and cell cluster basis.
Schizophrenia
SCZ is sometimes conceptualized as a neurodevelopmental disorder
most commonly manifesting in late adolescence and early adulthood
(Keshaban et al., 1994; Laurelle, 2000). Gene-ontology analyses of
genes differentially expressed in SCZ and healthy subjects revealed
alterations in pathways involved in ‘neurogenesis’, ‘neuronal differ-
entiation’ (Pedrosa et al., 2011) and ‘brain development’ (Wen
et al., 2014; Brennand et al., 2015). Two authors describe delayed
transformation and maturation of SCZ-derived cells (Pedrosa et al.,
2011; Yu et al., 2014). Murai et al. (2016) found increased micro-
RNA-219 expression which led to reduced neuronal stem cell prolif-
eration in SCZ patients carrying the DISC1 mutation. An
examination of microRNA expression in patients with SCZ carrying
the del(22q.11.2) mutation was conducted by Zhao et al. (2015).
Thirty-two microRNAs were signiﬁcantly upregulated, while 13
were downregulated. Gene-ontology analysis revealed, among other
ﬁndings, targets in various clusters important to neurological and
psychiatric disease. Yoon et al. (2014) observed that single nucleo-
tide polymorphisms (SNPs) in mediators of WAVE signalling
(ACTR2/Arp2) interact epistatically with CYFIP1 deletion (a gene
involved in del(15q11.2)) to increase the risk for SCZ. This epistasis
could be mediated by disturbances in apical polarity and adherence
junctions in affected neurons. Other authors have observed alter-
ations in gene transcription related to temporo-spatial cell identity
and adhesion (Brennand et al., 2011, 2015; Pedrosa et al., 2011).
Altered expression of miR-34 family expression was noted in
induced neurons derived from SCZ and schizoaffective (SZA) patients
carrying the del(22q11.2) mutation without reaching genome wide
signiﬁcance levels (Zhao et al., 2015). Passeri et al. (2015) observed
a signiﬁcantly higher transformation efﬁciency in cells derived from
patients carrying the del(16p.11.2) mutation compared to healthy sub-
jects using single-step transformation in an improved medium.
Abnormalities in cell morphology have been described in cells
derived from SCZ patients, however, no clear SCZ-related phenotype
could yet be established. Two studies noted reduced neurite outgrowth
(Brennand et al., 2011; Robicsek et al., 2013). Neurons derived from
DISC1 carriers displayed increased soma size and neurite length
2 weeks after transformation but not 4 weeks after transformation
(Wen et al., 2014). Cells differentially expressed genes from the
gene-ontology categories ‘brain development’, ‘synaptic transmission’
and ‘dentritic spine’. Topol et al. (2015), noticed over-expression of
translation-related proteins in SCZ-derived NPCs, but could not detect
any abnormalities in cell size that could account for this ﬁnding.
Cell motility plays a key role in brain development so that altered
cell migration could have neurodevelopmental implications in SCZ.
Fan et al. (2013) describe markedly increased mobility and reduced
adhesion in SCZ-derived olfactory neurospheres. Furthermore, SCZ-
cells proliferated more readily. Hypermobility was rescued by focal
adhesion kinase inhibition. Contradictory to these ﬁndings, Brennand
et al. (2015) observed reduced mobility in human-induced neuronal
SCZ-cells. In an earlier observation by Pedrosa et al. (2011), gene
ontology of signiﬁcantly differently expressed genes in induced SCZ-
neurons revealed ‘cell adhesion’ as an altered functional cluster. In
NPCs derived from a patient with SZA, impaired migration, which
coincided with preferential expression of a deﬁcient allele of
CNTNAP2 was observed. The patient’s not affected father, who car-
ried the same genetic deletion did not display aberrant cell migration
while primarily expressing the wild-type allele (Lee et al., 2015).
Reduction of NPC migration in SCZ is further corroborated by data
from two relatively large cohorts of Topol et al. An overall decreased
expression of microRNA-9 in SCZ was driven by a subset of patients
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below the 25% quantil of healthy subjects. miRNA-9 was correlated
with neurosphere migration, and the phenotype of impaired migration
in SCZ was attenuated by over-expression of miRNA-9. Marked dif-
ferences between SCZ and healthy subjects in miRNA-9 expression
could be observed in NPCs and early neurons, but not at 6 weeks
after transformation. miRNA-over-expression in healthy subjects as
well as SCZ-derived NPCs resulted in a trend towards alterations in
the protein expression in pathways related to ‘actin cytoskeleton’,
‘protein localization’ and ‘RNA processing’ (Topol et al., 2016).
Bipolar disorder
A variety of regulatory and neurodevelopmental alterations are
thought to play a role in BPD. The review of O’shea & McInnis
(2016) gives an overview on neurodevelopmental alterations in BPD
with a focus on iPSC models. Madison et al. noted signiﬁcant
reduction of cell proliferation in the bipolar offspring of two healthy
parents. In four of six iPSC lines derived from BPD, no differentia-
tion to NPCs was achieved. Propagation of NPCs past four or ﬁve
passages was laborious and could only be achieved for a subset of
iPSC lines of BPD. Proliferation of BPD-derived NPCs was
reduced, and paired box protein Pax-6 (PAX6) expression decreased.
Gene expression did not signiﬁcantly differ between BPD and
healthy subjects derived ﬁbroblasts and iPSCs, however, in NPCs,
18 genes showed > 1.5 fold difference in expression. Multiple genes
involved in spatial identity regulation were altered (NKX6-1, LEF1,
NEUROG1, NRG3 and SPARCL1; Madison et al., 2015).
Impairment of ventral-dorsal patterning and spatial identity was
described by Chen et al. (2014) who observed that cells derived
from BPD patients display increased DICER1, NKX2-1 and PAX2
expression (all of which promote ventral cell fate) and reduced
expression of EMX2 and HOXA1,6 and 7 (which promote dorsal cell
fate). Li+ reportedly up-regulates Wnt signalling (Valvezan & Klein,
2012), thus dorsalizing early NPCs (Wang et al., 2014). In cerebel-
lum slices of Li+-free BPD patients, signiﬁcantly elevated levels of
miR-34a were detected. In BPD iPSC-derived neuronal cells, inhibi-
tory effects of miR-34a on the expression of ANK3 and CACNB3
were described together with derogation of pre- and post-synaptic
development such as reduced dentritic branching (Bavamian et al.,
2015). In non-neuronal cells, miR-34a was earlier described as an
inhibitor of Wnt signalling (Hashimi et al., 2009).
Using a high-throughput label-free imaging platform (BIND scan-
ner) in BPD, Wang et al. (2014) could detect signiﬁcantly higher
peak wave length in cells derived from Li+ responders when com-
pared to Li+ non-responders. This suggests greater adhesion of cells
derived from Li+ responders when compared to non-responders.
None of the other parameters (cell count, cell fraction, and cell
perimeter) were signiﬁcantly different between healthy subjects and
BPD patients and Li+ responders and non-responders.
Findings on alterations in energy metabolism
Schizophrenia
Alterations of mitochondrial function metabolic stress are thought to
contribute to the development of SCZ (Rajasekaran et al., 2015).
Irrespective of treatment history, patients with SCZ differed from
healthy subjects in a micro-array analysis of genes relevant to
energy metabolism and oxidative stress. In a proteomics-analysis,
about half of the signiﬁcantly altered proteins were related to energy
metabolism and oxidative stress (Prabakaran et al., 2004). Employ-
ing non-reprogrammed SCZ-derived ﬁbroblasts, Fourier et al.
observed altered cell metabolism in response to oxidative stress in a
collective of ﬁrst-episode SCZ patients. Signiﬁcant changes were
observed in arginine-, extracellular matrix- and collagen-related
pathways. Fatty acid metabolism and neurotransmitter-related meta-
bolism were unaltered (Fournier et al., 2014). Alterations in energy
metabolism and reactive oxygen species (ROS) have been observed
on a genetic, morphological and functional level in human-induced
neuronal cell models of SCZ. Paulsen et al. did not note any alter-
ations in ATP-coupled respiration, but rather increased extra-mito-
chondrial O2 consumption and elevated levels of reactive oxygen
species (ROS). These changes occurred in SCZ-derived NPCs but
not in iPSCs or ﬁbroblasts. ROS-levels were rescued by treatment
with valproate (Paulsen Bda et al., 2012). In another study, the
same group observed elevated levels of potassium and zinc levels in
SCZ-derived NPCs again rescued by valproic acid treatment (Paul-
sen Bda et al., 2014). Increased levels of ROS and concomitantly
decreased mitochondrial membrane potentials and DNA damage
suggesting increased apoptosis were measured by Brennand et al.
(2015) In the same sample, cell-to-cell variability but not overall
expression of 70 kd heat-shock protein (HSP70) expression after
oxidative stress was signiﬁcantly elevated in SCZ. This ﬁnding is in
line with increased variability, but no changes in mean expression
of HSP70 expression following ethanol and methyl mercury stimuli
in SCZ-derived NPCs observed by Hashimoto-Torii et al. (2014). In
experiments performed by Robiscek et al., keratinocytes derived
from healthy subjects displayed baseline differences in O2 consump-
tion as compared to keratinocytes derived from patients with SCZ,
while their iPSCs did not differ in this regard. Inhibition of mito-
chondrial complex-one driven respiration by DA was signiﬁcantly
elevated in keratinocytes, as well as iPSCs and NPCs, derived from
SCZ patients. Alterations of mitochondrial network connectivity and
distribution of mitochondria were described in SCZ patients (Robic-
sek et al., 2013). Batalla et al. correlated neuronal glutamate-gluta-
mine (GLX) and N-acetylaspartate (NAA) with apoptotic markers in
non-reprogrammed ﬁbroblasts derived from ﬁrst-episode SCZ
patients in a combined cell culture and proton magnetic resonance
spectroscopy approach. The authors could establish a relationship
between decreased GLX and NAA levels in the anterior cingulate
and condensed chromatine in staurosporine-treated ﬁbroblasts sug-
gestive of excitotoxicity in the brain (Batalla et al., 2015).
In an approach integrating induced cell models and functional
magnetic resonance imaging (fMRI), D’Aiuto et al. (2015) investi-
gated possible relationships between latent Herpes simplex virus 1
infection and cognitive parameters in healthy subjects and SCZ
using induced neurons as a model for possible contributions of
infectious diseases to the pathogenesis of SCZ. However, induced
neurons and fMRI data were not derived from the same patients in
this study.
Bipolar disorder
BPD-derived neurons displayed a peculiar phenotype of overall
smaller mitochondria that showed greater function in the JC-1 -
mitochondrial membrane potential assay when compared to healthy
subjects. Li+ treatment rescued mitochondrial size but did not signif-
icantly alter membrane potential (Mertens et al., 2015).
Conclusions
Most studies investigating patients with SCZ were aiming to observe
an aetiologically homogeneous population, focusing on high-inci-
dence families and patients with high impact gene variants, which is
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a sensible approach for studying subtle alterations of genetic pertur-
bations, possibly giving cues for general mechanisms underlying this
complex polygenetic and poly-aetiologic disorder (Marchetto &
Gage, 2014). Identiﬁcation of alterations in well-deﬁned cases may
facilitate the examination of larger, more heterogenous populations.
The examination of iPSC-derived DA neurons from a pair of
monozygotic twins discordant for Parkinson’s disease, while carry-
ing a distinct predisposing mutation, yielded signiﬁcantly different
ﬁndings in monoamine oxidase B (MAO-B) activity and DA avail-
ability (Woodard et al., 2014). This can be interpreted as proof of
concept, suggesting that also non-genetic effects may be observed in
reprogrammed cells. The method may thus allow for the identiﬁca-
tion of biological correlates of environmental contributions to com-
plex disorders, in particular in phenotype-discordant monozygotic
twins. As the majority of clinical cases are sporadic rather than
monogenetic or familial, many aspects may, however, be overlooked
when restricting research to twins discordant for a certain disorders.
Attempts to recruit patients with distinct clinical parameters have
been made. In particular, observing patients with distinct reaction
patterns to medication, such as clozapine resistance (Paulsen Bda
et al., 2012) or Li+ responsiveness (Chen et al., 2014; Wang et al.,
2014) might be interesting.
In any case, for reprogrammed cells to hold their promise of
modelling ‘brain disease in a dish’ (Marchetto & Gage, 2012) and
start playing a prominent role in testing and development of
medicinal compounds or pathogenetic studies, more work needs to
be done. There are some ﬁndings discussed earlier, where loxapine
(Brennand et al., 2011), valproic acid (Paulsen Bda et al., 2012,
2014), or Li+ (Mertens et al., 2015) could revert alterations
observed in cells derived from patients with SCZ or BPD. For the
time being, it is unclear whether any of these observations would
be predictive of clinical efﬁcacy of a compound, or if the observed
alterations translate to pathologies in vivo. There are still plenty of
pieces missing in the puzzle of modelling psychiatric disorders
in vitro. To be able to interpret ﬁndings from reprogrammed cell
assays, a robust link between clinical traits and observations in cell
culture systems has to be established. In order to achieve compara-
bility between studies, meticulous description of the reprogrammed
cells’ phenotype and expression patterns is paramount. As eluci-
dated by the example of discrepant ﬁndings between the repro-
gramming of adult cells from patients with SCZ to dopaminergic
neurons (Robicsek et al., 2013; Hook et al., 2014) mentioned ear-
lier, a ﬁnding or lack thereof might not be interpretable without
thorough characterization of the cell. As neither TH nor DAT are
truly unique to dopaminergic midbrain neurons (Ciliax et al.,
1999), a whole battery of tests is necessary to pinpoint cellular
identity. Electrophysiological behaviour, tempo-spatial identity,
gene expression, characteristic proteins, pharmacological sensitivity
and morphology should, where appropriate, be used to conﬁrm
comparability of ﬁndings achieved with different reprogramming
techniques. Reprogramming remains a volatile procedure, where
small alterations in the protocol might change the outcome. In the
case of single-step reprogramming to DA neurons, it has been
shown that dish surface characteristics inﬂuence reprogramming
efﬁciency and cell morphology (Yoo et al., 2015). While it may
be impossible to ascertain in how far a reprogrammed cell repre-
sents an in vivo counterpart, thorough characterization of its char-
acteristics will help to increase faith in the validity of the model
(Srikanth & Young-Pearse, 2014; Hartley et al., 2015).
Data from cell cultures and genetic analysis will need to be inte-
grated with imaging studies, speciﬁcally PET and fMRI, to create a
more comprehensive picture of psychiatric disorders (Brennand &
Gage, 2011). To the best of our knowledge, only two publications
combine imaging data and cell culture ﬁndings trying to crosslink
information in a meaningful way. The study of D’Aiuto et al. (2015)
primarily employed cell culture techniques to prove the concept of
latent HSV-1 infection in human neuronal cells. Batalla et al. (2015)
did not utilize reprogrammed cells, but attempted to directly correlate
in vitro with in vivo data. Surprisingly, strong correlations between
brain metabolites and behaviour of cultured cells were found. Estab-
lishing correlations between single-cell phenomena, clinical features
and imaging data in individual patients may facilitate the interpreta-
tion of in vitro ﬁndings in the future. Many features of cultured cells
can be altered by the reprogramming process or remnants thereof, as
well as by non-physiological circumstances such as the presence of
immature cells in the culture, lack of synaptic contacts and glia, or
loss or disturbance of the epigenetic imprint. Furthermore, cell cul-
ture and imaging techniques yield profoundly different data. For
instance, increased cell size in vitro does not necessarily correspond
to altered volumes in MRI studies. When going beyond describing
differences between healthy subjects and patients, clear hypotheses
regarding pathophysiological phenomena likely to occur on a single-
cell basis may be helpful. PET in particular could establish a link
between in vivo and in vitro observations by correlating factors such
as receptor availability or neuro-transmitter release with genetic and
cell culture data. Unlike fMRI, which is limited to observations on a
network level, PET is able to visualize targets on a molecular scale.
Once cellular and clinical phenotypes have been put into relation, it
may be possible to predict clinical outcomes, such as response to
medication, based on cell culture models.
If only a speciﬁc phenomenon or marker is of interest rather than
the process of development and maturation per se, it would be desir-
able to identify just the right cell type suited for the assay, and to
convert cells in a single-step method. This way, the sample size can
be increased allowing for the recruitment of a more realistic study
population without sacriﬁcing too much statistical power. However,
the role of cell maturity and possible effects of the source cells’ epi-
genetic imprint will have to be considered.
A recent meta-analysis of PET imaging data on the DA system in
patients with SCZ has yielded large effect sizes for results indicating
a pre-synaptic dysfunction of the DA system in SCZ (Howes et al.,
2012). There are well-established imaging procedures for quantify-
ing DA release and synthesis in vivo, as well as reliable reprogram-
ming techniques yielding functional dopaminergic midbrain neurons
of high purity. The pre-synaptic disturbance of the dopaminergic
system therefore seems to be an accessible and promising target for
further experiments. As antipsychotic drugs commonly interfere with
dopaminergic transmission by blocking post-synaptic D2/3 receptors,
establishing an in vitro model of pre-synaptic DA dysfunction in
SCZ might also facilitate drug development or pre-clinical testing of
antipsychotic compounds in the future.
On the other hand, many research questions regarding early brain
development in SCZ, the development of psychosis, and brain alter-
ations in subjects who are at risk mental state for psychosis remain
unanswered. In the future, more complex traits, in particular neuro-
developmental perturbations, could be successfully modelled in
organoids (Marchetto & Gage, 2014). Brain organoids comprise
multiple neuronal and glial cell types, resembling the brain in early
pregnancy (Lancaster et al., 2013; Lancaster & Knoblich, 2014). As
of today, development of brain organoids beyond an early stage is
hindered by the lack of vascularization, so that later developmental
stages remain inaccessible. Some events predisposing to the out-
break of SCZ, such as intra-uterine infection, birth trauma or season-
ality of birth occur during pregnancy and might to some extent be
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modelled in vitro. While some proportion of the genetic loci increas-
ing the risk for SCZ are assumed to impact early brain development,
others might not contribute to the appearance of the phenotype until
much later in life.
Techniques of cell reprogramming
The process of reprogramming an adult somatic cell is dependent on
multiple factors each potentially inﬂuencing the induced cells’ phe-
notype and function. Until now, multiple cell types of different ori-
gin have been successfully reprogrammed. However, as of yet, no
cell type has been shown to be clearly superior. Even while compar-
atively difﬁcult to harvest, skin ﬁbroblasts remain the most common
source, possibly because there are many protocols readily available
in the literature. Despite their individual advantages, alternative, cell
types such as CD34+ blood cells, squamous cells derived from
urine, or hair follicle keratinocytes are as of yet rarely used. The
properties, advantages and disadvantages of various cell types are
reviewed by (Raab et al., 2014). The impact of the original cells is
not conﬁned to traits such as reprogramming efﬁciency, availability
or number of published methods, but stretches into the realm of epi-
genetics. DNA and histone methylation patterns remain partly that
of the tissue of origin, so that iPSCs differentiate most readily to
closely related cells (Kim et al., 2011; Vaskova et al., 2013). One
recent examination did, however, come to the conclusion that
genetic and epigenetic constitution of the donor outweigh cell-type
effects (Kytt€al€a et al., 2016). By treatment with chromatin-modify-
ing compounds or secondary and tertiary reprogramming, the differ-
entiation-inhibiting properties of epigenetic memory can be
attenuated (Kim et al., 2010). However, as a cell’s epigenetic
imprint might inﬂuence a disease-relevant phenotype, such proce-
dures remain controversial.
In order to successfully reprogram adult somatic cells, either to a
different cell type or stem cells, the selected transcription factors
must be delivered to the cell. Multiple vectors have been reported
so far, each bearing beneﬁts and disadvantages, so that it remains an
individual choice which system to employ for a speciﬁc problem.
For a comprehensive analysis of reprogramming vectors, see (Hu,
2014). In addition to high reprogramming efﬁciency, the ability to
enter the desired cell, safety, price and the dynamics of transgene
silencing are key points of interest for vectors in research. As there
are at the time being no ambitions for the development of cell thera-
pies based on reprogrammed cells in psychiatry, the issues of onco-
genic transcriptional factors as well as immunogenicity of many
vectors and, to a lesser extent, the mutagenicity of integrating vec-
tors are of limited concern.
In most studies considered for this review, patient-derived cells
were ﬁrst reprogrammed to iPSCs and later differentiated to NPCs
and/or any neuronal population. Today, there are various published
methods for the generation of patient-derived neurons either through
reprogramming to iPSCs, or through direct transformation of adult
cells to functional neuronal cells. (Tran et al., 2013) Depending on
the research issue, either method has its merits. While iPSCs offer
the possibility to observe developmental steps as they would occur
in utero, single-step reprogramming techniques have the advantage
of being less costly and laborious. Although directly converted cells
reach a mature phenotype much faster than iPSC-derived cells
(Caiazzo et al., 2011; Kriks et al., 2011), it remains unresolved
whether this is a beneﬁt allowing for rapid observation of functional
differences, or whether it is a limitation, possibly omitting pathologi-
cal steps in development while keeping much of the epigenetic
imprint of the tissue of origin.
Today, a multitude of reprogramming techniques exists. First,
direct conversion of ﬁbroblasts to dopaminergic midbrain neurons
by forced expression of the factors published by Vierbuchen et al.
(2010) (Ascl1, Brn2 and Myt1 l) together with Lmx1a and FoxA2
(Pﬁsterer et al., 2011), or solely Mash1, Nurr1 and Lmx1a (Caiazzo
et al., 2011) was reported. As of yet, a variety of protocols for the
generation of speciﬁc neuronal populations have been published.
Second, starting from protocols promoting neural induction and
functional ﬂoor plate formation using human embryonic stem (hES)
cells (Chambers et al., 2009; Fasano et al., 2010). Kriks et al.
(2011) developed a method for generating dopaminergic neurons
with marker proﬁle and distinct electrophysiological features remi-
niscent of those peculiar of human midbrain development. In this
case, the required co-expression of FoxA2 and LMX1 typical of
mature dopaminergic neurons is obtained by combining inhibitors of
the transcription factors SMAD, sonic hedgehog agonists and
GSK3B inhibition-mediated Wnt signalling activation. Along with
the optimization of methods to produce 2D cultures representative
of speciﬁc types of neurons, it is worth mentioning the recent efforts
made to generate 3D neuronal model systems that have proven use-
ful to model neuro-developmental diseases (Lancaster et al., 2013;
Mariani et al., 2015; Qian et al., 2016). In particular, developing
forebrain cerebral organoids showing signiﬁcant overlap between
differentially expressed genes and SCZ risk genes, as well as mid-
brain cerebral organoids speciﬁcally expressing dopaminergic neuron
markers were recently obtained from iPSCs (Qian et al., 2016).
Although comprehensive physiological characterization is not yet
available, midbrain organoids expressing dopaminergic neuron
markers are generated starting from previously successful protocols
used to model Parkinson’s disease (Kriks et al., 2011) and show a
relative early appearance of mature TH-expressing neurons. Consid-
ering the cell mass-fold expansion typical of 3D organoids, such a
protocol would have the advantage of yielding high numbers of neu-
rons in a cost-effective way and relatively short time, representing a
valid alternative to 2D cultures. However, a limitation of the system
might be the poorly deﬁned identity of the cellular population
obtained by this method: At day 65 only about half of the FoxA2 -
expressing neurons were also showing TH expression. While obvi-
ously not suitable for certain applications, like transplantation in ani-
mal models, the self-organization observed in such organoids might
reﬂect a more reliable approximation of the early steps in the matu-
ration of the developing midbrain and thus represent an advantage
in in vitro studies, e.g. when the role of mutations on proper neu-
ronal maturation is hypothesized.
Cell maturity is likely to play an important role in the interpreta-
tion of data acquired from induced human neuronal cells. While
cells derived from older individuals are reprogrammed at a lower
efﬁciency than cells derived from younger individuals, reprogram-
ming to an iPSC state seems to rejuvenate the cell (Li et al., 2009;
Mahmoudi & Brunet, 2012). The relevance of cell donor age is
however questioned, as other groups reported efﬁcient reprogram-
ming of ﬁbroblasts from elderly individuals (Marchetto et al.,
2010). Furthermore, an increase in iPSCs reprogramming efﬁciency
appears to be achievable from both, high ﬁbroblast passage number
and aged donors, respectively, through inhibition of the upregulated
cell cycle factor p21, potentially expanding sample typology (Troko-
vic et al., 2015).
Another point worth discussing are limitations of modelling SCZ
through reprogrammed neurons: a population of ﬁbroblast-derived
early neurons at 6 weeks differentiation and neuronal progenitor
cells derived from patients with SCZ and healthy subjects resembled
ﬁrst trimester neuronal cells regarding gene-expression patterns
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(Brennand et al., 2015). The onset of psychotic illnesses such as
SCZ and BPD is most common in late adolescence and early adult-
hood, however, a proportion of patients will develop ﬁrst symptoms
in infancy or much later in life (Kessler et al., 2005; Jones, 2013).
Even though SCZ is associated with subtle unspeciﬁc deﬁcits in
social functioning, motor skills and cognition before a prodromal
phase occurs (Murray et al., 2006), and even though some traits like
anxiety, attention-deﬁcit and subclinical changes in mood can pre-
date BPD by many years (Serra et al., 2015), those alterations do
not occur in all individuals and are not necessarily causally linked
to the development of psychosis. Immature cells resembling cell
populations found in the prenatal age can most likely be employed
to model alterations of cellular functioning very early in the devel-
opment of those disorders, as discussed above. However, they do
not necessarily reﬂect pathological mechanisms occurring later in
life. As an example, considering the role attributed to age as a cen-
tral aetiological factor in the ﬁeld of neurodegenerative diseases,
progerin treatment has been shown to substantially accelerate the
process of maturation and degeneration in iPSCs, resulting in a good
model for Parkinson’s disease (Miller et al., 2013). Having this in
mind, additional cellular model systems should be explored to
mimic the effects of age-related effects on the onset of psychotic
disorders.
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